Renaissance Venture Capital's Spring DEI UnDemo Day bridges the gap between underrepresented founders and venture capital, creating opportunities for diverse ...
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials